Antidote's EU Green Light Brightens Pradaxa Sales Outlook
This article was originally published in Scrip
The positive opinion granted by the European Medicines Agency to a reversal agent that is expected to be used very rarely brings Boehringer Ingelheim one step closer to a potential healthy injection of additional sales for its anticoagulant Pradaxa (dabigatran). Datamonitor Healthcare predicts that Pradaxa revenues in the EU could rise by 15% by 2020, should the Pradaxa antidote Praxbind (idarucizumab) be approved this year. This is now expected following the positive recommendation from the EMA's Committee for Medicinal Products for Human Use (CHMP).